Key Points
- Vicki Sato sold 22,000 shares of Vir Biotechnology on Dec. 1 at an average price of $6.00 for $132,000, leaving her with 1,188,391 shares (a 1.82% reduction in her stake).
- The stock was down about 7.2% and opened at $5.63 (12‑month range $4.16–$14.45); the company missed quarterly expectations with EPS of $(1.17) vs. $(0.70) expected and revenue of $0.24M vs. $1.98M expected.
- Sell‑side sentiment is mostly positive—nine Buys, one Hold and one Sell—with an average price target of $17.30, and institutional investors own roughly 65% of the shares, with several funds recently increasing positions.
Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) Director Vicki Sato sold 22,000 shares of the business's stock in a transaction on Monday, December 1st. The shares were sold at an average price of $6.00, for a total transaction of $132,000.00. Following the transaction, the director owned 1,188,391 shares in the company, valued at $7,130,346. This trade represents a 1.82% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Vir Biotechnology Trading Down 7.2%
Vir Biotechnology stock opened at $5.63 on Wednesday. Vir Biotechnology, Inc. has a 12-month low of $4.16 and a 12-month high of $14.45. The firm has a 50-day moving average price of $5.78 and a 200-day moving average price of $5.33. The firm has a market capitalization of $783.25 million, a PE ratio of -1.56 and a beta of 1.34.
Vir Biotechnology (NASDAQ:VIR - Get Free Report) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($1.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.47). The firm had revenue of $0.24 million during the quarter, compared to analysts' expectations of $1.98 million. Vir Biotechnology had a negative return on equity of 50.76% and a negative net margin of 2,963.54%.The business's revenue for the quarter was up .8% compared to the same quarter last year. During the same period last year, the company earned ($1.56) earnings per share. As a group, sell-side analysts predict that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
VIR has been the topic of several recent analyst reports. HC Wainwright reiterated a "buy" rating and issued a $15.00 price target on shares of Vir Biotechnology in a report on Monday, September 15th. Bank of America upgraded Vir Biotechnology from a "neutral" rating to a "buy" rating and increased their target price for the stock from $12.00 to $14.00 in a research note on Wednesday, August 27th. Evercore ISI initiated coverage on Vir Biotechnology in a research report on Wednesday, September 3rd. They set an "outperform" rating and a $12.00 target price for the company. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of Vir Biotechnology in a report on Monday. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $17.30.
Read Our Latest Stock Analysis on Vir Biotechnology
Institutional Trading of Vir Biotechnology
Hedge funds have recently added to or reduced their stakes in the business. ARCH Venture Management LLC purchased a new position in Vir Biotechnology during the 2nd quarter valued at about $65,100,000. Orbimed Advisors LLC boosted its stake in shares of Vir Biotechnology by 5.9% during the second quarter. Orbimed Advisors LLC now owns 2,380,715 shares of the company's stock valued at $11,999,000 after purchasing an additional 132,466 shares in the last quarter. Aberdeen Group plc boosted its stake in shares of Vir Biotechnology by 51.6% during the third quarter. Aberdeen Group plc now owns 1,526,265 shares of the company's stock valued at $8,715,000 after purchasing an additional 519,374 shares in the last quarter. Millennium Management LLC increased its holdings in Vir Biotechnology by 129.2% during the third quarter. Millennium Management LLC now owns 1,396,504 shares of the company's stock valued at $7,974,000 after buying an additional 787,212 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its stake in Vir Biotechnology by 9.8% in the first quarter. Charles Schwab Investment Management Inc. now owns 1,374,874 shares of the company's stock worth $8,909,000 after buying an additional 122,219 shares in the last quarter. 65.32% of the stock is owned by hedge funds and other institutional investors.
Vir Biotechnology Company Profile
(
Get Free Report)
Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
